Capivasertib Effective in AKT-Mutated Cancers
The investigational AKT inhibitor capivasertib (AZD5363) demonstrated clinical activity in patients with AKT-mutated cancers, suggesting the validity of tailoring treatment to tumor genes.
Source: OncLive